Several other research analysts also recently commented on HALO. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine upgraded Zogenix from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Finally, Cantor Fitzgerald began coverage on Veru in a report on Monday, July 1st. They issued an “overweight” rating and a $6.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $21.00.
HALO opened at $16.58 on Friday. The business has a 50-day moving average of $16.15. The company has a current ratio of 2.95, a quick ratio of 2.72 and a debt-to-equity ratio of 0.07. Halozyme Therapeutics has a 12 month low of $13.24 and a 12 month high of $18.85.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Arete Wealth Advisors LLC purchased a new position in Halozyme Therapeutics during the 4th quarter valued at about $3,461,000. Geode Capital Management LLC increased its holdings in Halozyme Therapeutics by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 1,520,657 shares of the biopharmaceutical company’s stock valued at $22,247,000 after purchasing an additional 76,753 shares during the period. 361 Capital LLC increased its holdings in Halozyme Therapeutics by 11.0% during the 1st quarter. 361 Capital LLC now owns 177,474 shares of the biopharmaceutical company’s stock valued at $2,857,000 after purchasing an additional 17,601 shares during the period. William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics during the 1st quarter valued at about $6,519,000. Finally, Private Advisor Group LLC purchased a new position in Halozyme Therapeutics during the 4th quarter valued at about $226,000. Hedge funds and other institutional investors own 82.07% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.